- Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431
- Inhibitors discovered at Domainex via virtual and fragment screening
Vienna, Austria and Saffron Waldon, UK, 9th November 2020 / Sciad Newswire / APEIRON Biologics AG, a privately-held biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex Ltd to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery.
Under the terms of the…
Appleyard Lees IP LLP has recently announced it has been recognised by three top legal industry analysts in the past month.
Eminent legal publishers Chambers & Partners 2021 has named Appleyard Lees a leading intellectual property firm for another consecutive year. Also, several Appleyard Lees attorneys are listed in IP Stars 2021, while The Legal 500 2021 has named Appleyard Lees a leading law firm for its patent and trade mark prosecution work.
In all three programmes, client feedback plays a large part in the research undertaken to rate a firm or attorney.
Appleyard Lees Managing…
Neuroscience-focused CRO Transpharmation opening new facility at Discovery Park
Phase of expansion for company as it joins growing life sciences community on site
Sandwich, Kent, November 4 2020 - Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, is pleased to welcome contract research organisation Transpharmation Ltd as a new tenant. Its new facility will be Transpharmation’s largest laboratory. The company, which is focused on neuroscience research, has over 100 clients worldwide.
Mayer Schreiber, CEO of Discovery Park, said, ‘We are…
Aditum Bio, established by industry veterans Joe Jimenez and Mark Fishman, to fund clinical development
Sosei Heptares to receive an upfront payment and strategic equity stake in Tempero Bio, plus future success-based milestone payments and tiered royalties
Tokyo, Japan and Cambridge, UK, 2 November 2020 – Sosei Group Corporation (“the Company”; TSE: 4565) has entered into an agreement1 with Tempero Bio, under which Tempero Bio has in-licensed exclusive global rights to Sosei Heptares’ mGlu5 negative allosteric modulator (NAM) program to develop therapies targeting substance use…
Cambridge, UK (November 2, 2020) — BioStrata, a specialist life science marketing and PR agency, has appointed a new senior team member to support continued and significant client growth in the United States. Jessica Grant, a B2B communications specialist with over 16 years’ experience, joins BioStrata as an Account Director based in Portland, Oregon, further building the company’s established global footprint.Jessica brings to BioStrata extensive experience in a broad mix of marketing and communications tactics across several sectors, with deep expertise in PR, content development,…
Leaders in stem cell research and cell therapy to help drive development of scalable off-the-shelf therapies for diseases with a high unmet clinical need
Cambridge, UK, 02 November 2020: Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has expanded its Scientific Advisory Board (SAB) with the appointment of three new members. Profs. Christine Mummery, Graziella Pellegrini and Giulio Cossu will apply their experience in the transition of stem cell approaches from proof-of-concept…
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Horizon Discovery Group plc (LSE: HZD) (“Horizon”) are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire Horizon for approximately $383 million (£296 million). The transaction has a total enterprise value of approximately $368 million (£284 million), is expected to close in the first quarter of 2021 subject to customary closing conditions.
With this investment, PerkinElmer will expand its portfolio of leading,…
RaDaR ctDNA liquid biopsy test to be used to monitor patient response in Phase 1/2 study of MVC-101 in multiple tumor types
Research Triangle Park, NC, USA and Cambridge, UK, 29 October 2020 – Inivata, a leader in liquid biopsy, today announces a collaboration with Maverick Therapeutics (“Maverick”) for the use of Inivata’s RaDaR™ assay for the detection and monitoring of residual disease and recurrence. RaDaR will be used to monitor circulating tumor DNA (ctDNA) in patients enrolled in the Phase 1/2 study of MVC-101, Maverick’s lead program…
• Announcing the challenge
This week the 7th CSP Blind Test begins - a major challenge in computational chemistry. It will see the world leading methods in Crystal Structure Prediction put to the test on real targets - with a high bar set by previous work. The 7 test systems have been sourced from leading experimentalists in industry and academia for prediction.
• The importance of CSP
The 3D structure and packing of crystalline materials have a big impact on their properties - this is most relevant in drug discovery and development.
Small molecule drugs are usually administered in…